FMR LLC 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 09:50 am Purchase |
2024-11-08 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 14,755,604 11.484% |
1,490,226 (+11.23%) |
Filing |
| 2024-08-12 09:40 am Purchase |
2024-08-09 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 13,265,378 10.484% |
2,922,981 (+28.26%) |
Filing |
| 2024-02-09 08:35 am Sale |
2024-02-08 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 10,342,397 8.239% |
-3,200,428 (-23.63%) |
Filing |
| 2023-02-09 08:23 am Sale |
2023-02-09 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 13,542,825 11.005% |
-4,397,195 (-24.51%) |
Filing |
| 2022-02-09 09:09 am Purchase |
2022-02-08 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 17,940,020 14.999% |
1,848,075 (+11.48%) |
Filing |
| 2021-02-08 10:15 am Sale |
2021-02-05 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
FMR LLC | 16,091,945 13.850% |
-628,430 (-3.76%) |
Filing |